Adaptive designs are increasingly used in clinical trials and digital experiments to improve estimation efficiency by updating treatment randomization probabilities as data accumulate. While most existing work focuses on settings with a single-stage treatment, adaptive designs for longitudinal studies with multi-stage, time-varying treatments remain relatively underexplored. In this work, we develop a general semiparametric efficiency framework for designing longitudinal adaptive experiments to optimize the estimation efficiency of a broad class of target estimands of interest. An efficiency-oriented design criterion is proposed to accommodate both single-estimand targets and joint optimization across multiple estimands. We demonstrate that optimal randomization at earlier stages depends on later-stage allocations, yielding a backward-recursive strategy for deriving the oracle design, and propose a longitudinal adaptive design to sequentially learn and target the oracle design using accumulating data. We further develop an adaptive-design-likelihood-based longitudinal targeted maximum likelihood estimator (ADL-LTMLE) for asymptotically normal and semiparametric efficient estimation of statistical estimands from dependent data collected from adaptive experiments, without relying on parametric model assumptions. Applying the framework to time-to-treatment-initiation effects that compare initiating treatment at a given stage with delaying initiation until a subsequent stage, we show that designs optimized for a particular stage-specific effect can substantially compromise estimation efficiency for effects defined at other stages, highlighting the design trade-offs addressed by our framework. Simulation studies show the proposed design and estimation approaches achieve substantial variance reductions relative to non-adaptive designs, with performance close to that of the oracle design.
Response-adaptive randomization (RAR) in clinical trials aims to improve ethical and statistical efficiency by dynamically allocating patients to treatments based on observed outcomes. While RAR based on a target optimal allocation have been extensively studied for two-arms settings, their extension to multi-treatment experiments ($K \geq 2$) remains theoretically fragmented, with most existing methods focusing on specific algorithms or restricted target allocations. In this paper, we introduce a unified framework for response-adaptive targeting, the $α$-Rebalancing Targeting Strategies ($α$RTS), which generalize the ERADE two-armed strategy of Hu et al. [2009]. We prove that all designs in this family share fundamental asymptotic properties: strong consistency, asymptotic normality of allocation proportions and treatment effect estimators, and asymptotic efficiency. To address sparse target regimes (where some treatments are asymptotically eliminated), we further propose $α$RTS with Forced Exploration, a variant that guarantees infinite sampling for all treatments while preserving the asymptotic guarantees. Extensive simulations illustrate the finite-sample behavior of $α$RTS variants in a 3-armed context, highlighting in particular the critical role of forced exploration in sparse settings.